AstraZeneca Secures FDA Nod for TRUQAP in PTEN-Deficient Prostate Cancer

Event summary

  • AstraZeneca's TRUQAP (capivasertib) combination approved in the US for PTEN-deficient metastatic hormone-sensitive prostate cancer.
  • Approval based on CAPItello-281 Phase III trial results, showing a 19% reduction in disease progression or death risk.
  • FDA also approved a companion diagnostic test to detect PTEN deficiency in prostate cancer tumors.
  • The approval covers approximately 200,000 patients diagnosed annually with metastatic hormone-sensitive prostate cancer, including 35,000 in the US.
  • AstraZeneca is seeking similar approval in the EU based on the same trial data.

The big picture

This approval marks a significant milestone in precision oncology, targeting a specific biomarker (PTEN deficiency) in prostate cancer. The strategy aligns with broader industry trends toward biomarker-directed therapies, which aim to improve outcomes for patients with aggressive forms of cancer. AstraZeneca's success here could set a precedent for future approvals in oncology, particularly for treatments that combine targeted therapies with existing standards of care.

What we're watching

Regulatory Momentum
Whether AstraZeneca can secure similar approvals in other major markets, particularly the EU, based on the CAPItello-281 trial data.
Commercial Execution
The pace at which AstraZeneca can integrate the companion diagnostic test into clinical practice and drive adoption among oncologists.
Competitive Landscape
How this approval positions AstraZeneca against competitors developing targeted therapies for prostate cancer, particularly those focusing on PTEN-deficient tumors.

Related topics

Regulatory Approval